Lonza 4D-Nucleofector LV Unit for non-viral primary T-cell transfection

Saturday, 10 September, 2016 | Supplied by: Capsugel Australia Pty Ltd


Lonza has announced its 4D-Nucleofector LV Unit, the latest addition to the 4D-Nucleofector System, which expands non-viral primary T-cell transfection to a closed, larger-scale format. Nucleofector Technology is said to improve on traditional electroporation methods to deliver enhanced transfection efficiencies while using less substrate and with only a moderate impact on cell viability. It is suitable for scientists working with hard-to-transfect cell types, like primary blood cells or stem cells.

The system was designed with the scientist in mind, so transfection protocols established on the existing smaller-scale unit can be smoothly transferred to the large-scale unit without the need for re-optimisation. The fully closed system is also suitable for use in a regulatory environment as it can be controlled by 21 CFR Part 11-compatible software. The addition of this larger-scale transfection format allows scientists to translate the results of their research applications into potential therapeutic applications.

Online: lonzabioscience.com.au
Phone: 1300 657508
Related Products

Enzo Life Sciences PROTEOSTAT Protein refolding and aggregation sensing kit

The kit includes a comprehensive set of optimised screening reagents and conditions that...

Bio-Rad Laboratories ddPLEX ESR1 Mutation Detection Kit

The kit enables simultaneous detection, discrimination and absolute quantification of seven known...

AdipoGen Life Sciences InVivoKines recombinant fusion proteins

InVivoKines are recombinant fusion proteins for immunotherapeutic, preclinical and translational...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd